TY - JOUR
T1 - Three-month stability of the cogstate brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease
T2 - results from the Australian imaging, biomarkers, and lifestyle-rate of change substudy (AIBL-ROCS)
AU - Lim, Yen Ying
AU - Jaeger, Judith
AU - Harrington, Karra
AU - Ashwood, Tim
AU - Ellis, Kathryn A.
AU - Stöffler, Albrecht
AU - Szoeke, Cassandra
AU - Lachovitzki, Rebecca
AU - Martins, Ralph N.
AU - Villemagne, Victor L.
AU - Bush, Ashley
AU - Masters, Colin L.
AU - Rowe, Christopher C.
AU - Ames, David
AU - Darby, David
AU - Maruff, Paul
PY - 2013/6
Y1 - 2013/6
N2 - Large prospective studies of Alzheimer's disease (AD) have sought to understand the pathological evolution of AD and factors that may influence the rate of disease progression. Estimates of rates of cognitive change are available for 12 or 24 months, but not for shorter time frames (e.g., 3 or 6 months). Most clinical drug trials seeking to reduce or modify AD symptoms have been conducted over 12-or 24-week periods. As such, we aimed to characterize the performance of a group of healthy older adults, adults with amnestic mild cognitive impairment (aMCI), and adults with AD on the CogState battery of tests over short test-retest intervals. This study recruited 105 healthy older adults, 48 adults with aMCI, and 42 adults with AD from the Australian Imaging, Biomarkers, and Lifestyle study and administered the CogState battery monthly over 3 months. The CogState battery of tests showed high test-retest reliability and stability in all clinical groups when participants were assessed over 3 months. When considered at baseline, the CogState battery of tests was able to detect AD-related cognitive impairment. The data provide important estimates of the reliability, stability, and variability of each cognitive test in healthy older adults, adults with aMCI, and adults with AD. This may potentially be used to inform future estimates of cognitive change in clinical trials.
AB - Large prospective studies of Alzheimer's disease (AD) have sought to understand the pathological evolution of AD and factors that may influence the rate of disease progression. Estimates of rates of cognitive change are available for 12 or 24 months, but not for shorter time frames (e.g., 3 or 6 months). Most clinical drug trials seeking to reduce or modify AD symptoms have been conducted over 12-or 24-week periods. As such, we aimed to characterize the performance of a group of healthy older adults, adults with amnestic mild cognitive impairment (aMCI), and adults with AD on the CogState battery of tests over short test-retest intervals. This study recruited 105 healthy older adults, 48 adults with aMCI, and 42 adults with AD from the Australian Imaging, Biomarkers, and Lifestyle study and administered the CogState battery monthly over 3 months. The CogState battery of tests showed high test-retest reliability and stability in all clinical groups when participants were assessed over 3 months. When considered at baseline, the CogState battery of tests was able to detect AD-related cognitive impairment. The data provide important estimates of the reliability, stability, and variability of each cognitive test in healthy older adults, adults with aMCI, and adults with AD. This may potentially be used to inform future estimates of cognitive change in clinical trials.
KW - Alzheimer's disease
KW - Assessment
KW - Cognition
KW - Cognitive tests
KW - Neuropsychological tests
UR - http://www.scopus.com/inward/record.url?scp=84879190102&partnerID=8YFLogxK
U2 - 10.1093/arclin/act021
DO - 10.1093/arclin/act021
M3 - Article
C2 - 23552802
AN - SCOPUS:84879190102
SN - 1873-5843
VL - 28
SP - 320
EP - 330
JO - Archives of Clinical Neuropsychology
JF - Archives of Clinical Neuropsychology
IS - 4
ER -